Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) Receives Average Rating of “Hold” from Analysts
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has earned an average recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $23.00.
Several analysts have weighed in on JNP shares. HC Wainwright reissued a “hold” rating on shares of Juniper Pharmaceuticals in a report on Friday, May 5th. Roth Capital set a $12.00 target price on Juniper Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th. ValuEngine lowered Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BMO Capital Markets raised Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $31.00 to $34.00 in a report on Friday, July 14th.
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Juniper Pharmaceuticals by 7.6% in the fourth quarter. Renaissance Technologies LLC now owns 254,300 shares of the specialty pharmaceutical company’s stock valued at $1,424,000 after buying an additional 17,900 shares during the period. Acadian Asset Management LLC raised its stake in Juniper Pharmaceuticals by 6.6% in the first quarter. Acadian Asset Management LLC now owns 41,037 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 2,544 shares during the period. Algert Global LLC raised its stake in Juniper Pharmaceuticals by 28.9% in the first quarter. Algert Global LLC now owns 108,315 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 24,270 shares during the period. AWM Investment Company Inc. purchased a new stake in Juniper Pharmaceuticals during the first quarter valued at $475,000. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in Juniper Pharmaceuticals during the second quarter valued at $1,192,000. 36.75% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) Receives Average Rating of “Hold” from Analysts” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/12/juniper-pharmaceuticals-inc-nasdaqjnp-receives-average-rating-of-hold-from-analysts.html.
Shares of Juniper Pharmaceuticals (NASDAQ:JNP) traded down 4.81% during midday trading on Friday, hitting $4.45. 28,080 shares of the stock were exchanged. The firm has a 50 day moving average of $4.95 and a 200-day moving average of $4.73. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $7.15. The company has a market cap of $48.26 million, a price-to-earnings ratio of 5.75 and a beta of 0.28.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a return on equity of 21.49% and a net margin of 13.94%. The firm had revenue of $13.96 million for the quarter, compared to analyst estimates of $11.84 million. Equities analysts expect that Juniper Pharmaceuticals will post ($0.51) EPS for the current year.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.